Increased metastatic potential of residual carcinoma after transarterial embolization in rat with McA‑RH7777 hepatoma

Wang,Guang-Zhi; Fang,Zhu-Ting; Zhang,Wei; Qu,Xu-Dong; Qian,Sheng; Liu,Rong; Wang,Jian-Hua

doi:10.3892/or.2013.2820

Increased metastatic potential of residual carcinoma after transarterial embolization in rat with McA‑RH7777 hepatoma

Authors:
- Guang-Zhi Wang
- Zhu-Ting Fang
- Wei Zhang
- Xu-Dong Qu
- Sheng Qian
- Rong Liu
- Jian-Hua Wang
View Affiliations

Affiliations: Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
Published online on: October 25, 2013 https://doi.org/10.3892/or.2013.2820
Pages: 95-102

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Transarterial chemoembolization represents a first-line non-curative therapy for hepatocellular carcinoma (HCC), although the biological changes in the remaining cancer after embolization are not completely understood. In the present study, we examined whether transarterial embolization (TAE) enhances the metastatic potential of residual HCC and investigated the mechanisms underlying embolization. The hepatoma cell line McA-RH7777, which is marked by green fluorescent protein (GFP), was used in the study. The invasion of cells cultured under hypoxia and normoxia was observed using the Transwell assay. Twenty male buffalo rats were implanted with GFP transfected McA-RH7777 tumors in the left lateral lobe of the liver. After laparotomy and retrograde placement of a catheter into the gastroduodenal artery (on the 14th day after implantation), TAE using lipiodol (0.2 ml/kg) was performed. Tumor volumes were measured before and after treatment using magnetic resonance imaging (MRI). Lung metastases were observed using fluorescence imaging, and the molecular changes of residual tumor cells were evaluated by western blotting or immunohistochemistry. The invasion assays indicated that the number of invading hypoxic cells was significantly higher than that of normoxic cells (30.2±2.46 vs. 20.4±1.89, P=0.013). Accompanying an increase in hypoxia-inducible factor-1α (HIF-1α) expression, the metastatic potential of tumor cells following hypoxia or TAE was enhanced. This enhanced metastatic potential was indicated by a significant reduction in the expression of E-cadherin and an upregulation of N-cadherin and vimentin expression. The number of lung metastases in the TAE group was 19.20±1.76, whereas this number was 11.30±1.54 in the control group, which represented a statistically significant difference (P=0.003). In conclusion, hypoxia in the residual tumor after TAE can increase the invasiveness and metastatic potential of HCC and may be responsible for the failure of TAE.

View Figures

View References

1	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 56:908–943. 2012.PubMed/NCBI
2	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
3	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar
4	Hasegawa K, Makuuchi M, Takayama T, et al: Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 49:589–594. 2008. View Article : Google Scholar : PubMed/NCBI
5	Chen MS, Li JQ, Zheng Y, et al: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 243:321–328. 2006. View Article : Google Scholar
6	Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
7	Fernandez M, Semela D, Bruix J, Colle I, Pinzani M and Bosch J: Angiogenesis in liver disease. J Hepatol. 50:604–620. 2009. View Article : Google Scholar
8	Llovet JM, Schwartz M and Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 25:181–200. 2005. View Article : Google Scholar : PubMed/NCBI
9	Sala M, Fuster J, Llovet JM, et al: High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl. 10:1294–1300. 2004. View Article : Google Scholar : PubMed/NCBI
10	Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 37:429–442. 2003. View Article : Google Scholar : PubMed/NCBI
11	Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 35:1164–1171. 2002. View Article : Google Scholar : PubMed/NCBI
12	Virmani S, Rhee TK, Ryu RK, et al: Comparison of hypoxia-inducible factor-1α expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol. 19:1483–1489. 2008.
13	Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ and Cao GW: Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 49:523–529. 2008. View Article : Google Scholar
14	Sergio A, Cristofori C, Cardin R, et al: Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 103:914–921. 2008. View Article : Google Scholar : PubMed/NCBI
15	Shim JH, Park JW, Kim JH, et al: Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 99:2037–2044. 2008.
16	Friedl P and Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 3:362–374. 2003. View Article : Google Scholar : PubMed/NCBI
17	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
18	Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
19	van Zijl F, Zulehner G, Petz M, et al: Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 5:1169–1179. 2009.
20	Choi SS and Diehl AM: Epithelial-to-mesenchymal transitions in the liver. Hepatology. 50:2007–2013. 2009. View Article : Google Scholar
21	Copple BL: Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-β-dependent mechanisms. Liver Int. 30:669–682. 2010.PubMed/NCBI
22	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
23	De Larco JE, Wuertz BR, Manivel JC and Furcht LT: Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res. 61:2857–2861. 2001.PubMed/NCBI
24	Ankoma-Sey V, Wang Y and Dai Z: Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology. 31:141–148. 2000. View Article : Google Scholar : PubMed/NCBI
25	Kan Z, Phongkitkarun S, Kobayashi S, et al: Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology. 237:151–158. 2005. View Article : Google Scholar : PubMed/NCBI
26	Maataoui A, Qian J, Mack MG, et al: Liver metastases in rats: chemoembolization combined with interstitial laser ablation for treatment. Radiology. 237:479–484. 2005. View Article : Google Scholar : PubMed/NCBI
27	Ramsey DE, Kernagis LY, Soulen MC and Geschwind JF: Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 13:S211–S221. 2002. View Article : Google Scholar : PubMed/NCBI
28	Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
29	Ivan M, Kondo K, Yang H, et al: HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O₂ sensing. Science. 292:464–468. 2001.
30	Brahimi-Horn MC, Chiche J and Pouyssegur J: Hypoxia and cancer. J Mol Med (Berl). 85:1301–1307. 2007. View Article : Google Scholar
31	Sendoel A, Kohler I, Fellmann C, Lowe SW and Hengartner MO: HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature. 465:577–583. 2010. View Article : Google Scholar : PubMed/NCBI
32	Daskalow K, Rohwer N, Raskopf E, et al: Role of hypoxia-inducible transcription factor 1α for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med (Berl). 88:817–827. 2010.
33	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
34	Gupta GP and Massague J: Cancer metastasis: building a framework. Cell. 127:679–695. 2006. View Article : Google Scholar : PubMed/NCBI
35	Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD and Kan Z: Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol. 41:516–521. 2006. View Article : Google Scholar : PubMed/NCBI
36	Liang B, Zheng CS, Feng GS, et al: Correlation of hypoxia-inducible factor 1α with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. Cardiovasc Intervent Radiol. 33:806–812. 2010.
37	Maataoui A, Qian J, Vossoughi D, et al: Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model. Eur Radiol. 15:127–133. 2005. View Article : Google Scholar : PubMed/NCBI
38	Abou-Alfa GK: TACE and sorafenib: a good marriage? J Clin Oncol. 29:3949–3952. 2011. View Article : Google Scholar : PubMed/NCBI
39	Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 119:1438–1449. 2009. View Article : Google Scholar : PubMed/NCBI